SARC-Sponsored Studies Selected for Oral Presentations at ASCO

SARC032 (A randomized trial of neoadjuvant RT and surgery with or without pembrolizumab for soft tissue sarcoma) has been selected for an oral presentation at the upcoming ASCO meeting. Dr. David Kirsch (above left) will be presenting the study on Monday, June 3rd during the Sarcoma session from 3-6pm CDT. Click here to learn more about SARC032.

SARC037 (A Phase I/II Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour Infusion in Ewing Sarcoma Patients in Combination with Low Dose Irinotecan and 3′-Deoxy-3′-18F Fluorothymidine (18F-FLT) Imaging) has been selected for an oral presentation at the upcoming ASCO meeting. Dr. Patrick Grohar (above right) will be presenting the study on Monday, June 3rd during the Sarcoma session from 3-6pm CDT. Click here to learn more about SARC037.